Home »
1995 Issues »
60 FR (08/29/1995) » 95-21323. Availability of Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Protective Peptides of Neurotoxin of C. Botulinum
95-21323. Availability of Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Protective Peptides of Neurotoxin of C. Botulinum
[Federal Register Volume 60, Number 167 (Tuesday, August 29, 1995)]
[Notices]
[Page 44860]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-21323]
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Availability of Non-Exclusive, Exclusive, or Partially Exclusive
Licensing of U.S. Patent Application Concerning Protective Peptides of
Neurotoxin of C. Botulinum
AGENCY: U.S. Army Medical Research and Material Command, DoD.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the
availability of U.S. Patent Application SN 08/446,114, entitled
``Protective Peptides of Neurotoxin of C. Botulinum,'' and filed May
19, 1995, for licensing. This patent has been assigned to the United
States Government as Represented by the Secretary of the Army.
ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command,
ATTN: Command Judge Advocate, Fort Detrick, Maryland 21702-5012.
FOR FURTHER INFORMATION CONTACT:
Mr. John F. Moran, Patent Attorney, 301-619-2065 or telefax 301-619-
7714.
SUPPLEMENTARY INFORMATION: A plasmid-based expression vector has been
constructed for genetic fusion of antigenic peptides to cholera toxin,
which is predicted to eliminate many of the problems associated with
direct conjugation of large proteins to the B subunit of this protein.
Cholera toxin fusion proteins can be used to improve the immunogenicity
of any vaccine and allow immunization by any number of different
routes. These fusion proteins may also aid in the treatment of
autoimmune disorders by inducing oral tolerance to the target antigen
conjugated to cholera toxin. The described methods allows bacterial
expression of fusion protein in sufficient quantities for vaccine and
diagnostic use.
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 95-21323 Filed 8-28-95; 8:45 am]
BILLING CODE 3710-08-M
Document Information
- Published:
- 08/29/1995
- Department:
- Defense Department
- Entry Type:
- Notice
- Action:
- Notice.
- Document Number:
- 95-21323
- Pages:
- 44860-44860 (1 pages)
- PDF File:
-
95-21323.pdf